A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Retavase Online, Description, Chemistry, Ingredients - Reteplase
Retavase Online, Description, Chemistry, Ingredients - Reteplase
DESCRIPTION
Retavase® (Reteplase) is a non-glycosylated deletion mutein of tissue plasminogen
activator (tPA), containing the kringle 2 and the protease domains of human
tPA. Retavase® contains 355 of the 527 amino acids of native tPA (amino acids
1-3 and 176-527). Retavase® is produced by recombinant DNA technology in E.
coli. The protein is isolated as inactive inclusion bodies from E. coli, converted
into its active form by an in vitro folding process and purified by chromatographic
separation. The molecular weight of Reteplase is 39,571 daltons.
Potency is expressed in units (U) using a reference standard which is specific
for Retavase® and is not comparable with units used for other thrombolytic agents.
Retavase® is a sterile, white, lyophilized powder for intravenous bolus injection
after reconstitution with Sterile Water for Injection, USP (without preservatives).
Following reconstitution, the pH is 6.0 ± 0.3. Retavase® is supplied as a 10.4
U vial to ensure sufficient drug for administration of each 10 U dose. Each
single-use vial contains:
10.4 U (18.1 mg) Vial
|
Reteplase
|
18.1 mg
|
|
Tranexamic Acid
|
8.32 mg
|
|
Dipotassium Hydrogen Phosphate
|
136.24 mg
|
|
Phosphoric Acid
|
51.27 mg
|
|
Sucrose
|
364.0 mg
|
|
Polysorbate 80
|
5.20 mg
|
top
